Drug intelligence / Profile preview

Xihuang Jiedu Capsule

Development stage
Unknown
Lead developer
Guang'anmen Hospital
Modality
Small Molecules
Administration
Oral
01

Overview

Xihuang Jiedu Capsule is a traditional Chinese medicine (TCM) formulation developed and used primarily in China for the adjunctive treatment of various malignant tumors, including breast cancer, gastric cancer, colorectal cancer, liver cancer, and lung cancer. It is also indicated for conditions such as abscesses, lymphadenitis, multiple abscesses, and soft tissue infections characterized by swelling and pain. The capsule contains a combination of ingredients such as artificial bezoar (artificial niuhuang), artificial musk (artificial shexiang), frankincense (ruxiang), myrrh (moyao), Panax notoginseng (sanqi), American ginseng (xiyangshen), Cremastra appendiculata tuber (shancigu), Cordyceps sinensis powder (dongchongxiacao fen), pearl powder (zhenzhufen), among others. Its mechanism of action is based on TCM principles—clearing heat and toxins ("jiedu"), dispersing nodules ("sanjie"), activating blood circulation to remove stasis ("huoxue quyu"), reducing swelling ("xiaozhong"), and relieving pain ("zhitong"). Modern research suggests it may modulate the tumor microenvironment to exert anti-tumor effects and improve quality of life in patients with malignancies[2][4]. It is generally well tolerated but contraindicated in pregnancy; possible adverse reactions include gastrointestinal discomfort or allergic reactions in sensitive individuals[1][3].

Brand names
Xihuang Jiedu Capsule
Other names
西黄解毒胶囊西黄胶囊Xihuang Jiaonang
02

Targets

JUN (Transcription factor Jun)STAT3 (Signal Transducer and Activator of Transcription 3)MAPK14 (p38 mitogen-activated protein kinase alpha)IL-6 (Interleukin 6)VEGFA (Vascular endothelial growth factor A)JNK (Mitogen-activated protein kinase kinase kinase family)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)TP53 (Cellular Tumor Antigen p53 R175H)PTEN (Phosphatase and tensin homolog deleted on chromosome ten)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on Xihuang Jiedu Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xihuang Jiedu Capsule.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call